Skip to main content

We use cookies to understand how you use our site and to improve your experience.

This includes personalizing content and advertising.

By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.

You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.

In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.

You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.

OK Cancel

Back to top

NeurAxis, Inc. to Report Second Quarter 2026 Financial Results on August 11 and Host Conference Call

NeurAxis will announce Q2 2026 financial results and host a conference call on August 11, 2026.

Quiver AI Summary

NeurAxis, Inc., a medical technology company specializing in neuromodulation therapies for chronic conditions, plans to announce its financial results for the second quarter of 2026 on August 11, 2026, prior to market opening. A conference call to discuss these results will take place the same day at 9:00 am ET, with details provided for both U.S. and international callers. NeurAxis is focused on its proprietary IB-Stim® technology, which is FDA cleared for treating functional abdominal pain related to irritable bowel syndrome and other conditions in patients aged 8 and older. The company is also conducting additional clinical trials for PENFS in various pediatric and adult health issues. For more information, interested parties can visit their website.

Potential Positives

  • NeurAxis plans to report its second quarter financial results, indicating transparency and commitment to shareholder communication.
  • The company is advancing its proprietary IB-Stim technology, which is FDA cleared for treating functional abdominal pain in patients 8 years and older, showcasing the potential for market growth and impact on healthcare.
  • NeurAxis is engaged in additional clinical trials of its PENFS technology for pediatric and adult conditions, highlighting ongoing innovation and focus on addressing large unmet healthcare needs.

Potential Negatives

  • The press release does not provide any specifics regarding the financial results for the second quarter or any expected performance metrics, which may raise concerns among investors about the company's transparency and financial health.
  • The lack of detailed information on ongoing clinical trials and their outcomes could lead to uncertainty about the efficacy and adoption of NeurAxis's products, potentially impacting investor confidence.
  • The scheduling of the conference call only after the financial results have been reported may suggest a lack of proactive communication with investors, which could be viewed negatively in terms of investor relations.

FAQ

When will NeurAxis report its financial results?

NeurAxis will report its financial results for the second quarter on August 11, 2026, before market open.

What time is the NeurAxis conference call?

The NeurAxis conference call is scheduled for 9:00 am ET on August 11, 2026.

How can I access the NeurAxis conference call?

You can access the conference call toll-free at 1-877-270-2148 for U.S. and Canada or 1-412-317-6060 internationally.

What technology does NeurAxis specialize in?

NeurAxis specializes in neuromodulation therapies, particularly the IB-Stim® technology for treating chronic abdominal pain conditions.

Where can I find more information about NeurAxis?

For more information about NeurAxis, please visit their official website at http://neuraxis.com.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.


$NRXS Insider Trading Activity

$NRXS insiders have traded $NRXS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $NRXS stock by insiders over the last 6 months:

  • BRIAN ALLEN CARRICO (Chief Executive Officer) purchased 8,060 shares for an estimated $15,797
  • TIMOTHY ROBERT HENRICHS (Chief Financial Officer) purchased 7,593 shares for an estimated $14,882
  • THOMAS JOESEPH CARRICO (CRO, CCO, CPO) purchased 667 shares for an estimated $1,307

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$NRXS Hedge Fund Activity

We have seen 13 institutional investors add shares of $NRXS stock to their portfolio, and 7 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • MARSHALL WACE, LLP added 78,695 shares (+inf%) to their portfolio in Q1 2026, for an estimated $582,343
  • RENAISSANCE TECHNOLOGIES LLC added 76,954 shares (+inf%) to their portfolio in Q1 2026, for an estimated $569,459
  • CENTIVA CAPITAL, LP added 50,833 shares (+inf%) to their portfolio in Q1 2026, for an estimated $376,164
  • T3 COMPANIES, LLC removed 29,921 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $218,722
  • BLACKROCK, INC. added 27,354 shares (+inf%) to their portfolio in Q1 2026, for an estimated $202,419
  • PANORAMIC CAPITAL, LLC added 25,000 shares (+15.2%) to their portfolio in Q1 2026, for an estimated $185,000
  • GEODE CAPITAL MANAGEMENT, LLC added 17,452 shares (+23.1%) to their portfolio in Q1 2026, for an estimated $129,144

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Full Release

CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its second quarter period ended June 30, 2026, on Tuesday, August 11, 2026, before market open. The Company has scheduled a conference call for the same day, Tuesday, August 11, 2026, at 9:00 am ET to review the results.

Conference Call Details

Date and Time: Tuesday, August 11, 2026, at 9:00am ET

Toll Free: 1-877-270-2148 (U.S. and Canada toll-free) International: 1-412-317-6060
Webcast: https://app.webinar.net/E5zrP9X7wLY

Replay : Toll Free: 1-855-669-9658 (U.S. and Canada toll-free) International: 1-412-317-0088
Replay access code: 8443629
Webcast: https://app.webinar.net/E5zrP9X7wLY

About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.

For more information, please visit http://neuraxis.com .

Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com


Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Due to inactivity, you will be
signed out in approximately: